Literature DB >> 8976288

Scar contracture: cellular and connective tissue aspects in Peyronie's disease.

H P Ehrlich1.   

Abstract

PURPOSE: The understanding of the mechanism of how the plaque in Peyronie's disease causes functional distortions is presented in terms of scar formation and maturation. The repair process is important for survival. The expected biological response to tissue loss and disruption is scarring but in some situations, such as Peyronie's disease, the resultant scar creates major problems.
MATERIALS AND METHODS: The development of scar involves the deposition of connective tissue which histologically can be studied in patients and in animal models as well as with in vitro models. Abnormal scarring can involve excessive connective tissue deposition. Clinically examples of excess scarring are hypertrophic scars common in healed burn patients and keloid scars seen in patients with this inherited defect in healing. In addition to excessive connective tissue deposition, another aspect of abnormal scarring is scar contracture, when the compaction of the scar tissue distorts the anatomical appearance and functional capacity of adjacent tissues and organs. The fibroblast populated collagen lattice model demonstrates the organization of connective tissue in a controlled environment and the information gained can be related to scarring.
RESULTS: The compaction of scar tissue involves the reorganization of collagen fibers by resident fibroblasts using cell tractional forces rather than cell contraction forces. These findings were documented with the fibroblast populated collagen lattice model. In Peyronie's disease the distortion caused by the scar or plaque is neither related to scar contracture nor active compaction of scar tissue but, rather, the expansion of the surrounding unscarred tissue and the inflexibility of the scar tissue composing the plaque.
CONCLUSIONS: Peyronie's disease plaques are rigid structures due to the organization of the deposited collagen fibers. Those fibers are independent in their connective tissue organization, which makes the plaque incompatable with adjacent structures.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8976288     DOI: 10.1016/s0022-5347(01)65368-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

2.  The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.

Authors:  Robert A Gelfand; Dolores Vernet; Istvan Kovanecz; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2014-12-11       Impact factor: 3.802

3.  The role of intrinsic pathway in apoptosis activation and progression in Peyronie's disease.

Authors:  Carla Loreto; Giampiero La Rocca; Rita Anzalone; Rosario Caltabiano; Giuseppe Vespasiani; Sergio Castorina; David J Ralph; Selim Cellek; Giuseppe Musumeci; Salvatore Giunta; Rados Djinovic; Dragoslav Basic; Salvatore Sansalone
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

Review 4.  Adjunctive maneuvers to treat urethral stricture: a review of the world literature.

Authors:  Omer A Raheem; Jill C Buckley
Journal:  Transl Androl Urol       Date:  2014-06

5.  A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's Disease: a pilot study.

Authors:  L Toscano; M V Rezende; L F Mello; D Paulillo; S Glina
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.